

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Kallikrein 8/Neuropsin in direct ELISAs and Western blots.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Kallikrein 8 Gln29-Gly260 Accession # O60259
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Neutralization	Optimal dilution of this antibody should be experimentally determined.
Western Blot	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Kallikrein 8 (KLK8), also known as neuropsin or ovasin, is a member of the human tissue kallikrein family (1). Two alternatively spliced forms exist, resulting in 260 (isoform 1) and 305 (isoform 2) amino acid sequences, respectively (2). Isoform 1 consists of a signal peptide (residues 1 to 28), a short pro peptide (residues 29 to 32) and the mature chain (residues 33 to 260). Isoform 2 is identical to isoform 1, except that a 45 amino acid segment is inserted in isoform 2 between residues 23 and 24 in isoform 1. Isoform 1 is predominantly expressed in pancreas whereas isoform 2 is preferentially expressed in adult brain and hippocampus, although both forms are expressed in fetal brain and placenta in comparable levels. The brain function of KLK8 seems evident in neuropsin knockout mice that showed abnormalities of synapses and neurons and predisposition to global seizure activity (3, 4). KLK8 is a novel marker for ovarian and cervical cancer carcinomas (5, 6). Recombinant human KLK8, after being activated by lysyl endopeptidase, can cleave fibronectin and several small peptide substrates (7, 8). This activity can be inhibited by rhSerp1 A5, rhSerp1 F2 and AEBSF (R&D Systems, Catalog # 1266-PI, 1470-PI and EI001, respectively). Recombinant human KLK8 produced by R&D Systems corresponds to isoform 1.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.